On February 10, 2026 Mabqi reported it’s participation in the World ADC Congress, taking place in London, UK, from February 23 to 26.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Widely regarded as the leading global event focused on antibody–drug conjugates (ADCs), the congress unites key stakeholders from across the entire ADC value chain — spanning early discovery, linker–payload innovations, and clinical translation.

During the event, Anne Chevrel will disclose new preclinical data on our lead pH-sensitive antibody–drug conjugate, showcasing our expertise in targeted delivery and enhanced therapeutic efficacy.

Our delegation will include:
• Anne Chevrel, Head of Discovery & Technology
• Sylvain Yon, CEO
• Cécile Durand, Business Development Director

We look forward to engaging with the global ADC community and discussing innovative strategies shaping the next generation of antibody–drug conjugates.

(Press release, Mabqi, FEB 10, 2026, View Source [SID1234662570])